GLP Receptor Agonist

Lixisenatide (Leu-¹³C₆,¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.

GLP-1 receptor agonist 18 is an orally active GLP-1 receptor agonist with an EC₅₀ of 0.22 nM. GLP-1 receptor agonist 18 can reduces blood sugar levels and body weight. GLP-1 receptor agonist 18 can be used for the research of diabetes.

Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.

GLP-1R agonist 40 (Compound I-1) is an orally active, potent and selective GLP-1R agonist (EC₅₀ = 26.7 pM for cAMP accumulation). GLP-1R agonist 40 shows significant decrease in blood glucose levels. GLP-1R agonist 40 can be used in the research of type 2 diabetes.

GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC₅₀ of <10 nM.

GLP-1R agonist 29 (Compound 20) is the agonist for GLP-1R that induces hGLP-1R mediated cAMP stimulation with an EC₅₀ of 0.018 nM. GLP-1R agonist 29 exhibits good pharmacokinetics characteristics with good body exposure of AUC_0-∞,sc of 77688 ng·h/mL.

GLP-1R agonist 45 is a full GLP-1R agonist with an EC₅₀ of 2.20 nM. GLP-1R agonist 45 can be used in the research of type 2 diabetes and obesity.

GLP-1R agonist 25 (compound 13) is a GLP1-R agonist, with an EC₅₀ of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research.